# OncoLOGY TRIALS AT PRMC

## Breast

**A011502 (ABC)** - A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer Criteria: Node Positive HER2 Negative Breast Cancer

**A011401** - Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

**A221505** - Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast. Criteria: Post Mastectomy Radiation Therapy with Breast Reconstruction

**S1418/NRG-BR006** - A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with \(\geq 1\) CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy. Criteria: Triple Negative Breast Cancer with Residual Invasive Cancer or Positive Lymph Nodes

**EA1131** - A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Breast Cancer following Neoadjuvant Chemotherapy Residual

## Lung

**A151216** - Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial. Criteria: Patients With Resectable or Resected Lung Cancer

**A081105** - Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer

**E4512** - A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

**EA5142** - Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) – A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

**CALGB 30610** - Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide


**NRG-CC003** - Randomized Phase III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer

**LungMAP** - A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer

## Colon

**A021502** - Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy Criteria: Stage III Colon Cancer and Deficient DNA Mismatch Repair.

## Ovarian

**NRG-GY005** - Randomized Phase III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS). Criteria: Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

## Prostate

**NRG-GU002** - Phase II/III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following RP with or without Adjuvant Docetaxel Criteria: Post Radical Prostatectomy Radiotherapy and Androgen Deprivation

**NRG-GU005** - Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer

---

**All Types of Cancers**

Communication Skills Training for Cancer Patients and their Care Partners.

Johns Hopkins Clinical Research Network

Contact: (410) 543-7006 or e-mail: cancer.care@peninsula.org or research@peninsula.org